The following statement is from last year after the last placing.
The net proceeds from the Placing will be used to strengthen the Company's balance sheet as partnering discussions progress and provide working capital to continue to develop the Company's portfolio of early-stage, high-value small molecule programmes. The net proceeds of the Placing are expected to provide the Company with at least twelve months working capital.
Glad to be out for now, lots of positive stories out there re what trials Tiz are going to do.....but big trials (not 2 people) cost big money, which they don't have...gla